Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
APG222
- Development stage
- Preclinical
- Lead developer
- Apogee Therapeutics
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous, Subcutaneous
01
Overview
APG222 is a bispecific monoclonal antibody developed by Apogee Therapeutics. It is designed to simultaneously inhibit interleukin-13 (IL-13) and OX40 ligand (OX40L), two key immune signaling molecules implicated in inflammatory and immunological diseases. By targeting both IL-13 and OX40L, APG222 aims to provide dual blockade of type 2 inflammation (via IL-13 inhibition) and broader immune modulation (via OX40L inhibition). The drug features an extended half-life for less frequent dosing. Its primary indication under development is atopic dermatitis, with potential for other inflammatory and immunological disorders[1][2][3].
- Other names
- APG 222APG222APG-222
02
Targets
IL-13 (Interleukin-13)TNFSF4 (Tumor necrosis factor ligand superfamily member 4)
Beyond the preview
Go deeper on APG222.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on APG222.